ARID3A

Across TCGA pan-cancer cohorts, ARID3A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARID3A data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARID3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARID3A expression acts as an unfavorable survival marker.

HNSC, LUAD, and ACC are the cancer types where ARID3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.115	0.768	<.001	48	view →
LUAD	DFS	Median	All	0.049	0.814	<.001	6	view →
ACC	DFS	Median	III,IV	0.048	0.457	.015	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARID3A–HNSC (OS)

Open the HNSC breakdown →